Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
VTYX

VTYX - Ventyx Biosciences, Inc. Stock Price, Fair Value and News

2.51USD-0.24 (-8.73%)Market Closed

Market Summary

VTYX
USD2.51-0.24
Market Closed
-8.73%

VTYX Stock Price

View Fullscreen

VTYX RSI Chart

VTYX Valuation

Market Cap

177.7M

Price/Earnings (Trailing)

-0.92

Price/Free Cashflow

-0.97

VTYX Price/Earnings (Trailing)

VTYX Profitability

Return on Equity

-62.74%

Return on Assets

-58%

Free Cashflow Yield

-103.49%

VTYX Fundamentals

VTYX Earnings

Earnings (TTM)

-192.6M

Earnings Growth (Yr)

0.92%

Earnings Growth (Qtr)

17.5%

Breaking Down VTYX Revenue

Last 7 days

-12.2%

Last 30 days

-46.8%

Last 90 days

-62.4%

Trailing 12 Months

-92.5%

How does VTYX drawdown profile look like?

VTYX Financial Health

Current Ratio

22

VTYX Investor Care

Shares Dilution (1Y)

20.39%

Diluted EPS (TTM)

-3.24

Tracking the Latest Insider Buys and Sells of Ventyx Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
mohan raju
acquired
19,355
0.2
96,778
ceo and president
Apr 12, 2024
nsv partners iii lp
sold
-
-
-695,339
-
Apr 12, 2024
subramaniam somu
sold
-
-
-695,339
-
Apr 02, 2024
nuss john
sold
-8,921
5.4034
-1,651
chief scientific officer
Apr 02, 2024
auster martin
sold
-7,591
5.4035
-1,405
chief financial officer
Apr 02, 2024
mohan raju
sold
-23,299
5.4034
-4,312
ceo and president
Apr 02, 2024
krueger christopher w
sold
-8,921
5.4036
-1,651
chief business officer
Mar 28, 2024
mohan raju
acquired
-
-
11,843
ceo and president
Mar 28, 2024
auster martin
acquired
-
-
4,531
chief financial officer
Mar 28, 2024
krueger christopher w
acquired
-
-
4,531
chief business officer

1–10 of 50

Which funds bought or sold VTYX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-944
-
-%
May 29, 2024
Opaleye Management Inc.
added
12.72
4,251,700
7,067,500
1.54%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
17,435,000
17,435,000
0.08%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.64
45,618
62,618
0.01%
May 17, 2024
Ikarian Capital, LLC
added
8,483
2,777,450
2,792,060
0.31%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-90.00
-90,360
25,883
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-73.69
-472,719
668,789
-%
May 15, 2024
PDT Partners, LLC
new
-
662,761
662,761
0.06%
May 15, 2024
Redmile Group, LLC
added
944
11,390,900
11,902,700
0.44%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
sold off
-100
-1,755,680
-
-%

1–10 of 46

Are Funds Buying or Selling VTYX?

Are funds buying VTYX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VTYX
No. of Funds

Unveiling Ventyx Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 04, 2024
flynn james e
5.03%
3,542,000
SC 13G
Mar 21, 2024
cormorant asset management, lp
5.21%
3,670,000
SC 13G
Mar 13, 2024
nsv investments i, l.p.
7.1%
5,004,071
SC 13D/A
Mar 08, 2024
nsv investments i, l.p.
8.5%
5,004,071
SC 13D/A
Feb 23, 2024
point72 asset management, l.p.
5.0%
2,977,868
SC 13G
Feb 14, 2024
citadel advisors llc
5.9%
6
SC 13G/A
Feb 13, 2024
vanguard group inc
6.34%
3,741,925
SC 13G
Jan 29, 2024
blackrock inc.
6.5%
3,814,531
SC 13G
Jan 29, 2024
tang capital partners lp
5.2%
3,100,000
SC 13G
Dec 11, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of Ventyx Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
Jun 05, 2024
8-K
Current Report
May 17, 2024
3
Insider Trading
May 17, 2024
4
Insider Trading

Peers (Alternatives to Ventyx Biosciences, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.5B
6.8B
-6.49% 10.99%
-8.63
7.52
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.9B
2.0B
5.23% -22.79%
-59.96
9.94
75.20% 68.82%
16.1B
2.5B
9.54% -12.06%
78.29
6.51
13.74% 186.89%
14.0B
3.8B
8.61% 0.73%
18.78
3.72
8.58% 129.81%
MID-CAP
5.0B
107.9M
-7.86% 61.07%
-9.24
48.09
54.84% -28.31%
4.8B
524.1M
-6.67% -54.57%
-11.55
9.2
394.93% 39.61%
3.6B
251.0M
-3.70% -15.05%
-12.06
14.23
73.58% -86.73%
3.0B
240.7M
-5.00% -33.10%
-6.24
12.77
-1.03% -213.92%
2.4B
813.8M
-3.54% -38.85%
-1.4K
2.99
56.43% 98.83%
2.0B
996.6M
-5.63% 89.11%
-4.95
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-8.17% 14.57%
27.53
4.36
60.38% -34.49%
455.3M
881.7K
-5.75% 469.52%
-13.49
481.06
-77.61% 33.36%
209.1M
4.2M
-26.57% 40.10%
-1.67
50.27
-66.30% 48.24%
18.5M
2.1M
-8.15% 218.45%
-0.8
7.61
-13.45% 69.54%

Ventyx Biosciences, Inc. News

Latest updates
Defense World15 Jun 202407:29 pm
InvestorPlace09 May 202407:00 am
Yahoo Finance30 Apr 202407:00 am

Ventyx Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32020Q4
Assets19.6%332278322349389371420262278291149-
  Current Assets21.0%3202643083473873314182522582631460.00
    Cash Equivalents175.1%14252.0057.0052.0064.0065.0026345.0042.0071.0069.000.00
  Net PPE8.7%1.001.001.001.001.000.000.000.000.000.000.00-
Liabilities-25.7%25.0034.0038.0021.0018.0018.0037.0019.0019.0012.0012.0031.00
  Current Liabilities-34.7%15.0022.0026.0020.0017.0016.0036.0018.0018.0012.0012.001.00
Shareholder's Equity25.9%307244284328372354384243259279--
  Retained Earnings-9.2%-457-419-372-318-265-226-191-160-140-117-100-32.50
  Additional Paid-In Capital15.3%76566365764763758157640540139712.002.00
Shares Outstanding19.0%70.0059.0059.0059.0058.0057.0051.0051.0051.0050.003.002.00
Float----1,300---385----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations7.8%-47,625-51,655-34,664-49,282-30,921-47,264-23,989-14,792-12,726-14,687-11,041-9,903-3,019--
  Share Based Compensation6.5%6,5436,1458,0087,8686,5674,8284,1674,1313,4441,39396928880.00--
Cashflow From Investing-9.5%41,76546,12538,89134,819-18,895-140,84064,16218,250-16,503-143,090-73,163-11.001,899--
Cashflow From Financing16341.7%96,1845851,6252,47348,646-10,355177,79224986.00159,58250,37956,72556,865--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VTYX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development (includes related party amounts of $254 and $250, respectively)$ 33,747$ 35,437
General and administrative8,0217,115
Total operating expenses41,76842,552
Loss from operations(41,768)(42,552)
Other (income) expense:  
Interest income(3,227)(3,622)
Other expense311
Total other (income) expense(3,196)(3,621)
Net loss(38,572)(38,931)
Unrealized gain (loss) on marketable securities(62)539
Foreign currency translation(9)23
Comprehensive loss$ (38,643)$ (38,369)
Net loss per share, basic$ (0.62)$ (0.68)
Net loss per share, diluted$ (0.62)$ (0.68)
Weighted average common shares outstanding, basic61,829,97657,638,923
Weighted average common shares outstanding, diluted61,829,97657,638,923

VTYX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 141,898$ 51,579
Marketable securities160,684200,641
Prepaid expenses and other assets17,17712,125
Total current assets:319,759264,345
Property and equipment, net828762
Operating lease right-of-use assets10,41411,509
Restricted cash975975
Other long-term assets102102
Total assets332,078277,693
Current liabilities  
Accounts payable5,5835,756
Accrued expenses8,00515,508
Current portion of operating lease liabilities9461,001
Total current liabilities14,53422,265
Operating lease liabilities, net of current portion10,54811,505
Total liabilities25,08233,770
Commitments and contingencies (Note 5)
Stockholders' equity:  
Common stock, $0.0001 par value; 900,000,000 shares authorized at March 31, 2024 and December 31, 2023; 70,499,201 and 59,252,349 shares issued at March 31, 2024 and December 31, 2023, respectively; 70,493,906 and 59,239,113 shares outstanding at March 31, 2024 and December 31, 2023, respectively76
Additional paid-in capital764,869663,154
Accumulated other comprehensive loss(121)(50)
Accumulated deficit(457,759)(419,187)
Total stockholders' equity306,996243,923
Total liabilities and stockholders' equity$ 332,078$ 277,693
VTYX
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
 CEO
 WEBSITEhttps://ventyxbio.com
 INDUSTRYBiotechnology
 EMPLOYEES91

Ventyx Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Ventyx Biosciences, Inc.? What does VTYX stand for in stocks?

VTYX is the stock ticker symbol of Ventyx Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ventyx Biosciences, Inc. (VTYX)?

As of Thu Jun 20 2024, market cap of Ventyx Biosciences, Inc. is 177.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTYX stock?

You can check VTYX's fair value in chart for subscribers.

What is the fair value of VTYX stock?

You can check VTYX's fair value in chart for subscribers. The fair value of Ventyx Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ventyx Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VTYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ventyx Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether VTYX is over valued or under valued. Whether Ventyx Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ventyx Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTYX.